Post by AIRNA

AIRNA will be at the American Society of Gene & Cell Therapy Annual Meeting in May with two presentations showcasing data from our AATD and cardiometabolic portfolio.    Our oral presentation titled “AIR-001: A highly potent and precise GalNAc-conjugated RNA base editing treatment for alpha-1 antitrypsin deficiency” will detail the preclinical findings behind AIR-001, our lead candidate that has recently entered the clinic in the RepAIR1 trial.    We’ll also present a poster covering new preclinical data from our cardiometabolic portfolio. Titled “RNA Editing: A Modality for Precise Introduction of Gain-of-Function Variants Identified by Human Genetics,” it represents the first public presentation of the use of AIRNA’s RESTORE+ platform to perform gain-of-function RNA-editing in vivo.    Both presentations will take place on Tuesday, May 12. If you’re at ASGCT, we’d love to connect and share more about our work pioneering RNA-editing therapies for rare and common disease.    Learn more: https://lnkd.in/e2hVpaxF   #ASGCT2026 #RNAEditing